WHO Pharmaceuticals Newsletter 1999, No. 03&04
(1999; 16 pages)
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory actions
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Ouvrir ce répertoire et afficher son contenuNew developments
Fermer ce répertoireMedical devices
Afficher le documentBlood test for Lyme disease: approved: USA
Afficher le documentDrug delivery systems: new devices under development: UK, USA
Afficher le documentWound dressings: pain-free removal: UK
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Blood test for Lyme disease: approved: USA

United States of America. The Food and Drug Administration has approved a simple, new blood test for Lyme disease that can be used in a doctor’s office. The test: PreVue B. burdorferi Antibody Detection Assay: Chembio Diagnostic Systems: provides results in an hour, enabling doctors to make a probable diagnosis more quickly than with laboratory tests and to start treatment with antibiotics immediately.

The test is intended to be used as the first step in testing people suspected of having Lyme disease. Positive results must be confirmed with a Western blot test done by a laboratory. Two-stage testing is recommended by the Centers for Disease Control.

Diagnosing Lyme disease can be challenging because the symptoms of flu, fatigue and joint pain are similar to those of a number of other conditions. The new test uses antigenic proteins developed by recombinant DNA techniques rather than whole cell Borrelia burgdorferi preparations used in current laboratory tests: a technique that allows for more accuracy.

Reference: FDA Talk Paper T99-10, 16 February 1999.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013